Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Drug Pricing topic
No spam. Unsubscribe anytime.
Panel advances PBM reform and a drug affordability board with narrowed public-records exceptions
Summary
The committee reported two measures aimed at drug pricing oversight — PBM reform (SB 387) and a prescription drug affordability board (SB 401). Sponsors said targeted public-records exceptions are needed to protect proprietary commercial data while enabling regulators to access information needed for oversight.
The committee reported two related bills designed to increase oversight of prescription drug pricing and pharmacy benefit managers (PBMs), with sponsors stressing a balance between transparency and protection of proprietary business data.
Senator Bass, addressing a PBM-reform measure, said the proposed regulator will need discretion to classify certain submitted materials as proprietary in order to protect commercially sensitive data. "There's a lot of proprietary data that would be detrimental to those publicly traded companies in the event that it got out of their hands," Bass said, arguing that regulator discretion is standard for similar insurance filings.
Senator Talbot described a companion bill that would create a prescription drug affordability board to evaluate high-use medicines and produce regular reports to the legislature. He said the board would rely in part on information companies already submit to federal agencies and that technical amendments in committee narrowed the scope of records requiring special handling. "We're going to ask for the information that you're already providing to the federal government," Talbot said; supporters said that approach streamlines access for state oversight while minimizing new proprietary exposures.
Jason Young of Americans for Lower Drug Prices testified in support, saying targeted disclosure will help the state, plans and patients better understand pricing and improve policymaking. Industry groups registered opposition and asked for protections for proprietary formulas and commercial contracts; committee staff and sponsors said the bills were amended to limit special exceptions to narrowly defined information and that the insurance commissioner would screen claims of proprietary status.
Both bills were reported favorable after technical amendments and committee acceptance of a narrowed public-records approach. Sponsors and advocates said the measures aim to improve legislative access to pricing and utilization data without undermining companies' core trade secrets.
